Immunic Inc CEO Daniel Vitt talked with Proactive about the company's latest updates in the development of vidofludimus calcium, a drug positioned to treat all forms of multiple sclerosis (MS). Joining from New York after the company's MS R&D Day, Vitt highlighted the drug's mechanism of action, specifically its role as a Nurr1 activator, which could address neuroprotection in MS patients. Vitt emphasized how disability worsening occurs independently of relapses in MS patients and discussed the key unmet need this drug aims to address. He noted, “This drug is really poised to be used broadly on all forms of multiple sclerosis,” highlighting its potential impact on both relapsing and progressive MS. He also shared exciting upcoming data points, including futility analysis from the ENSURE phase 3 study and phase 2 CALLIPER results expected next April. For more interviews and updates on Immunic Inc's developments, visit Proactive's YouTube channel. Don’t forget to give this video a like, subscribe to the channel, and enable notifications for future content. #ImmunicInc #DanielVitt #MultipleSclerosis #MSResearch #VidofludimusCalcium #Nurr1Activator #ProgressiveMS #RelapsingMS #Pharma #Biotech #MSDrugDevelopment #ClinicalTrials#ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews